Glucocorticoid receptor + Muscarinic M3 + β2-adrenergic receptor (ICS/LAMA/LABA combination)

Class

ICS/LAMA/LABA triple fixed-dose combination (Breztri Aerosphere, HFO propellant)

Pathway

GR-mediated anti-inflammatory action, muscarinic antagonism blocking cholinergic bronchoconstriction, and beta-2 agonism relaxing airway smooth muscle combined

Notes

original target text: Glucocorticoid receptor (budesonide) + M3 muscarinic receptor (glycopyrrolate) + beta-2 adrenergic receptor (formoterol)

This combination pairs three receptor mechanisms that together address the two core problems of obstructive airway disease: inflammation and airway narrowing. The glucocorticoid receptor is an intracellular receptor that, once bound by a corticosteroid, alters gene transcription to dampen inflammatory signaling in the airway lining, reducing swelling, mucus production, and immune cell recruitment. The muscarinic M3 receptor is a cell-surface receptor activated by the neurotransmitter acetylcholine, and its stimulation contracts airway smooth muscle; blocking it prevents this nerve-driven narrowing. The beta-2 adrenergic receptor, when activated, triggers a signaling cascade that actively relaxes airway smooth muscle, providing bronchodilation through an independent route. Combining an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-2 agonist in one inhaler targets inflammation and two distinct bronchoconstriction pathways simultaneously, which single-mechanism or dual-mechanism inhalers cannot achieve as comprehensively. This triple-mechanism approach is relevant in chronic obstructive pulmonary disease and, in some cases, difficult-to-control asthma, where inflammation and multiple bronchoconstrictive drivers coexist and inadequate control with fewer mechanisms leads to symptom burden and exacerbations.